Table 3.
Trials ongoing with eculizumab in renal diseases and in renal transplantation
| Rank | Identifier | Status | Study name |
| 1 | NCT01221181 | Active | Eculizumab therapy for dense deposit disease and C3 nephropathy |
| 2 | NCT02093533 | Recruiting | Eculizumab in primary MPGN |
| 3 | NCT01275287 | Active | Targeting complement activation in ANCA-vasculitis |
| 4 | NCT00844545 | Completed | Open label controlled trial of eculizumab in adult patients with plasma therapy-resistant aHUS |
| 5 | NCT00844844 | Completed | Open label controlled trial of eculizumab in adolescent patients with plasma therapy-resistant aHUS |
| 6 | NCT00844428 | Unknown | Open label controlled trial of eculizumab in adolescent patients with plasma therapy-sensitive aHUS |
| 7 | NCT00838513 | Unknown | Open label controlled trial of eculizumab in adult patients with plasma therapy-sensitive aHUS |
| 8 | NCT01194973 | Unknown | An open-label, multi center clinical trial of eculizumab in adult patients with aHUS |
| 9 | NCT01193348 | Unknown | An open label, Multi center clinical trial of eculizumab in pediatric patients with aHUS |
| 10 | NCT01755429 | Unknown | The safety and efficacy of eculizumab in Japanese patients with aHUS |
| 11 | NCT01522170 | Enrolling | aHUS observational long term follow up |
| 12 | NCT01522183 | Recruiting | aHUS registry |
| 13 | NCT01770951 | Completed | A retrospective, observational, non-interventional trial to assess eculizumab treatment effect in patients with aHUS |
| 14 | NCT02205541 | Not yet recruiting | Eculizumab in shiga-toxin related hemolytic and uremic syndrome pediatric patients |
| 15 | NCT01410916 | Completed | Safety and efficacy study of eculizumab in shiga-toxin producing Escherichia coli (STEC-HUS) |
| 16 | NCT01406288 | Completed | Completed outbreak of HUS linked to Escherichia coli of serotype 0104:H4 |
| 17 | NCT01756508 | Recruiting | Eculizumab for prevention and treatment of kidney graft reperfusion injury |
| 18 | NCT01919346 | Recruiting | Eculizumab for prevention of DGF in kidney transplantation |
| 19 | NCT01403389 | Active | A study of the activity of eculizumab for prevention of DGF in deceased donor transplant |
| 20 | NCT02142182 | Recruiting | A trial for prevention of DGF after kidney transplantation |
| 21 | NCT01567085 | Active | Safety and efficacy of eculizumab in the prevention of AMR in sensitized recipients of a kidney transplant from a deceased donor |
| 22 | NCT02113891 | Not yet recruiting | Eculizumab therapy for subclinical antibody-mediated rejection in kidney transplantation |
| 23 | NCT01095887 | Active | Eculizumab added to conventional treatment in the prevention of antibody-mediated rejection in blood group incompatible living donor kidney transplantation |
| 24 | NCT01106027 | Active | Dosing regimen of eculizumab added to conventional treatment in positive crossmatch deceased kidney yransplant |
| 25 | NCT01895127 | Recruiting | Efficacy and safety of eculizumab for treatment of antibody-mediated rejection following renal transplantation |
| 26 | NCT00670774 | Active | Dosing regimen of eculizumab added to conventional treatment in positive crossmatch living kidney transplant |
| 27 | NCT01399593 | Active | Safety and efficacy of eculizumab to prevent AMR in living donor kidney transplant recipients receiving desensitization |
| 28 | NCT01327573 | Active | Eculizumab therapy for chronic complement-mediated injury in kidney transplantation |
| 29 | NCT01029587 | Recruiting | Eculizumab to enable renal transplantation in patients with history of catastrophic antiphospholipid antibody syndrome |
MPGN: Membrano-proliferative glomerulonephritis; ANCA: Anti neutrophil cytoplasmic antibody; aHUS: Atypical hemolytic uremic syndrome; STEC-HUS: Shiga-toxin producing escherichia; DEGF: Delayed graft function; AMR: Antibody mediated rejection.